An open label, randomized, parallel, phase II trial to evaluate the efficacy and safety of cremophor-free, polymeric micelle formulation of paclitaxel compared to paclitaxel in subjects with ovarian cancer.

被引：0
|
作者：
Kim, Yong-Man
Lee, Shin-Wha
Cho, Chi Heum
Hur, Soo-Young
Kim, Byoung-Gie
Kim, Jae Hoon
Kim, Seung Cheol
Kim, Seok-Mo
Kim, Young-Tae
Ryu, Hee Sug
Kang, Soon-Beom
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[2] Keimyung Univ, Sch Med, Dept Obstet & Gynecol, Taegu, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea
[4] Sungkyunkwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Seoul, South Korea
[6] Ewha Womans Univ, Sch Med, Mokdong Hosp, Dept Obstet & Gynecol, Seoul, South Korea
[7] Chonnam Natl Univ, Sch Med, Dept Obstet & Gynecol, Kwangju, South Korea
[8] Yonsei Univ, Severance Hosp, Dept Obstet & Gynecol, Seoul 120749, South Korea
[9] Ajou Univ, Sch Med, Dept Obstet & Gynecol, Suwon 441749, South Korea
[10] Konkuk Univ, Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5568
引用
收藏
页数：1
相关论文
共 50 条
  • [31] An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary
    Daugaard, G.
    Fizazi, K.
    Huebner, G.
    Braumann, D.
    Rubinsak, J. R.
    Allouache, D.
    Rodriguez, G. I.
    Stahl, M.
    Fuglsang, L.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Phase II study of a polyethoxylated castor oil-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum
    Lee, J.
    Park, S.
    Lim, H.
    Kwon, J.
    Kim, G.
    Song, C.
    Hong, J.
    Kim, C.
    Ahn, H.
    Ahn, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [33] An open, multi-center, phase II clinical trial to evaluate efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer preliminary report.
    Chao, Y
    Li, CP
    Chao, TY
    Su, WC
    Hsieh, RK
    Wu, MF
    Yeh, KH
    Chen, LT
    Cheng, AL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 346S - 346S
  • [34] Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)
    Marchetti, Claudia
    Tudisco, Riccardo
    Salutari, Vanda
    Pietragalla, Antonella
    Scambia, Giovanni
    Fagotti, Anna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (08) : 1175 - 1178
  • [35] Efficacy and dose-dependent activity of ABI-007; a cremophor-free, nanoparticle paclitaxel, in first-line metastatic breast cancer: integrated results of 2 phase II trials.
    Ibrahim, NK
    Samuels, B
    Page, R
    Guthrie, T
    Doval, D
    Patel, K
    Nair, M
    Digumarti, R
    Hortobagyi, GN
    Rao, S
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S131 - S131
  • [36] Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial (vol 4, pg 135, 2024)
    Li, Rong
    Zhang, Hongping
    Li, Qingshui
    Yuan, Guangwen
    Zhou, Yanjie
    Yin, Rutie
    Wang, He
    Wang, Chunyan
    Huang, Yi
    Wang, Wei
    Yan, Xiaojian
    Wu, Lingying
    Zhou, Qi
    JOURNAL OF THE NATIONAL CANCER CENTER, 2025, 5 (01): : 93 - 93
  • [37] Efficacy and safety of sintilimab plus albumin-bound- paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial
    Wang, Yin
    Zhao, Jing
    Liang, Haixi
    Liu, Junxiu
    Huang, Shenjiao
    Zou, Guorong
    Huang, Xin
    Lan, Chunyan
    ECLINICALMEDICINE, 2023, 65
  • [38] A phase II study to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Liporaxel®, oral paclitaxel) compared to IV paclitaxel in patients with recurrent or metastatic breast cancer: OPERA (NCT03326102)
    Pluard, Timothy J.
    Sharma, Priyanka
    Melisko, Michelle E.
    Vidula, Neelima
    Weng, David E.
    Skelton, Jane D.
    Yoon, Koung Eun
    Cho, Hyun Ju
    Rugo, Hope S.
    CANCER RESEARCH, 2020, 80 (04)
  • [39] A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer
    Chelariu-Raicu, Anca
    Nick, Alpa
    Urban, Renata
    Gordinier, Mary
    Leuschner, Carola
    Bavisotto, Linda
    Dal Molin, Graziela Zibetti
    Whisnant, John K.
    Coleman, Robert L.
    GYNECOLOGIC ONCOLOGY, 2021, 160 (02) : 418 - 426
  • [40] An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika Paige
    Chu, Christina
    Richardson, Debra L.
    Arend, Rebecca Christian
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Hays, John L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345